$CSLLY News

CSL (ASX:CSL) After New CEO Pick Still Looks Undervalued In The Leading Narrative

CSL appoints ViiV Healthcare chief Deborah Waterhouse as CEO from February

Haemonetics shares jump as CSL sets 2027 rollout of plasma devices

HRMY vs. CSLLY: Which Stock Is the Better Value Option?

CSL (ASX:CSL) Could Be 15% Undervalued After Its $355 Million Alentis Deal

CSL to pay up to $1.6 bln to develop rare disease drug; shares rise

CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases

CSL Seqirus Expands U.S. Availability of Influenza Vaccine following Successful Completion of the 2026/27 Manufacturing Campaign

Why Is CSL (ASX:CSL) Launching Its New Flu Vaccine First In The UK?

Expanded ANDEMBRY Reimbursement In Canada Could Be A Game Changer For CSL (ASX:CSL)

Public Access to ANDEMBRY® (garadacimab) Expands Across Canada for the Prevention of Hereditary Angioedema (HAE) Attacks

Lancet Publication Marks Important Advance in Influenza Prevention for Older Adults

Lancet Publication Marks Important Advance in Influenza Prevention for Older Adults

CSL Ltd's Dividend Analysis

CSL Limited (CSLLY) Q4 2026 Earnings Call Transcript

CSL Limited 2026 Q4 - Results - Earnings Call Presentation

Is CSL An Unmissable Value Play?

CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)

CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union

CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union